Background: Percutaneous tricuspid repair using the edge-to-edge technique is a novel treatment option. More data are needed to better understand which aspects predict a favorable outcome Methods: Twenty high-risk patients (78.6 ± 8.3 years, EUROScore II 9.1 ± 7.7%, STS score 8.8 ± 4.3) with severe symptomatic tricuspid regurgitation (TR) were treated with the MitraClip ® system. All patients underwent standardized pre-, peri-, and post-procedural evaluation. Acute success was defined as successful edge-to-edge repair with TR reduction of ≥ 1 grade and survival until hospital discharge.Results: Fifteen (75%) patients showed acute success until discharge and 12 (60%) at 30-day follow-up. In 5 (25%) patients repair failed due to either unsuccessful clip implantation (n = 2), single leaflet device attachment (n = 1), TR reduction < 1 grade (n = 1), or in-hospital death (n = 1). Comparing patients with successful procedure versus those with failed repair revealed similar comorbidities but more severe right heart failure, lower left ventricular ejection fraction, worse renal function, and higher diuretic equivalent doses in the failed repair group. No differences in conventional echocardiographic parameters for TR severity but more dilated tricuspid annulus geometry (tricuspid valve [TV] annulus, coaptation depth, tenting area) in the failed repair group were observed. The success rate of non-central/nonanteroseptal jet location was only 25%. Conclusions:Tricuspid annulus geometry assessment may be of crucial importance and seems to impact procedural outcomes in patients undergoing edge-to-edge TV repair. Further investigations including advanced imaging are needed to better understand and treat this complex valve disease.
Seit Anfang des Jahres 2020 hat die durch die „coronavirus disease 2019“ (COVID-19) verursachte Pandemie weitreichende Folgen für die medizinische Versorgung in Deutschland und weltweit. Aktuell befindet sich Deutschland in der sog. 3. Pandemiewelle. Dazu kommen Mutanten des „severe acute respiratory syndrome coronavirus 2“ (SARS-CoV-2) mit erhöhter Virustransmission und schwerem Erkrankungsverlauf. Steigende SARS-CoV-2-Infektionszahlen münden in einer erhöhten Zahl schwerer COVID-19-Verläufe und einem erhöhten Bedarf intensivmedizinischer Behandlungen, die auf begrenzte strukturelle und personelle Ressourcen für COVID-19- und Non-COVID19-Patienten treffen. Dies – wie alle Situationen mit hoher Kapazitätsbelastung – macht eine Triagierung und Priorisierung von Erkrankten mit Zuteilung intensivmedizinischer Kapazitäten notwendig. Beide Strategien sind sinnvolle Organisationsformen und dürfen nicht mit einem Zusammenbruch der medizinischen Versorgung gleichgesetzt werden. Kardiovaskuläre Komorbiditäten und eine kardiale Mitbeteiligung bei COVID-19 sind für die Krankheitsschwere und den Krankheitsverlauf von besonderer Bedeutung. Neben der medizinischen Versorgung der Patienten mit pandemiebedingten akuten SARS-CoV-2-Infektionen müssen auch andere Patienten mit akuten, u. U. lebensbedrohlichen Erkrankungen unverändert mit hoher Qualität versorgt werden. Dieser Beitrag gibt eine aktuelle Übersicht über die vorgeschlagenen Restrukturierungsmaßnahmen in deutschen Krankenhäusern sowie damit einhergehenden Triagierungs- und Priorisierungsalgorithmen. Daneben ist es erforderlich, bestehende Behandlungsalgorithmen an die pandemische Lage zu adaptieren; dies wird aufgrund ihres besonderen Stellenwerts exemplarisch an kardiovaskulären Erkrankungen skizziert.
Background Due to increased operative mortality in high-risk patients treated for severe tricuspid regurgitation (TR), there is a growing interest in interventional therapy in these patients that are otherwise solely treated with medication. The edge-to edge technique with implantation of one or more MitraClips is an therapeutic interventional option for these patients. So far, data for transcatheter TR treatment are sparse. Purpose The present cohort study investigates safety, feasibility and effectiveness of the edge-to-edge technique treating severe TR after starting a transcatheter TR treatment program at our institution in 2017. Methods A total of 17 high-risk patients (79.18±8.76 years, EUROScore II 9.31±8.23%, table) with symptomatic, severe TR were treated using the MitraClip system from 12/2017 until 12/2018. All patients received pre-interventional clinical, echocardiographic and invasive evaluation and were entered into a database. Safety and feasibility of the procedure, reduction of TR grade and clinical outcomes were collected and analyzed at the day of discharge and at 30-day follow-up. Results MitraClip device was successfully implanted in 16 of 17 patients (94.1%). In one patient grasping of the leaflets was impossible due to bad echo conditions by abdominal air. 76.5% of the patients had severe or massive and 23.5% had a torrential TR (figure). A total of 25 Clips were used (22 in anteroseptal, 3 in posteroseptal commissure). No intraprocedural deaths, emergency surgery or major vascular complications occurred. Postprocedural TR was significantly reduced (TR reduction ≥1 grade) from a mean TR grade of 3.8±0.8 at baseline to 1.74±0.59 postprocedural (p<0.001, table and figure). One patient had device detachment before discharge. There was one death due to progressive cardiogenic shock 4 days after the procedure. However, the procedure was planned as a last therapeutic option in this terminally ill patient. Echocardiography at discharge showed reduction of TR in 82,4% of patients (mean TR grade at discharge 2.21±0.66, p<0.001). At 30 day f/u symptoms were significantly improved from inital mean NYHA class of 3.06±0.56 to a mean NYHA class of 2.55±0.52 (p=0.002) and patients presented with reduced TR (mean TR grade at 30 day f/u 2.58±0.57, p<0.001). Conclusion Interventional treatment of severe TR in high-risk and mostly inoperable patients using the MitraClip technique is safe and effectivly reduces TR grade leading to clinical improvement. However, further investigations are needed to identify clear parameters highly predictive for a favorable acute and midterm procedural success. Also, more data and clinical trials are needed to determine the long-term course in these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.